2026-01-27 - Analysis Report
**Company Overview**
Merck is a global pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical, biotechnology, and healthcare products.

**Return Rate Comparison**

* **Review Stock (MRK):** Cumulative return over 69.17%
* **Comparison Stock (VOO):** Cumulative return of 127.58%
* **Divergence:** -56.00, relative divergence: 28.60%

The divergence between the review stock (MRK) and the comparison stock (VOO) is -56.00 percentage points. This is a relatively significant difference, with the comparison stock having a higher cumulative return.

**Alpha, Beta Analysis**

| Period | CAGR | MDD | Alpha | Beta | Cap (B) |
|--------|------|-----|-------|------|---------|
| 2016-2018 | 33.0% | 15.3% | 25.0% | 0.7 | 182.1B |
| 2017-2019 | 39.0% | 15.3% | 14.0% | 0.7 | 216.8B |
| 2018-2020 | 29.0% | 24.7% | 5.0% | 0.7 | 195.0B |
| 2019-2021 | -1.0% | 24.7% | -65.0% | 0.6 | 191.4B |
| 2020-2022 | 41.0% | 22.9% | 36.0% | 0.5 | 277.1B |
| 2021-2023 | 49.0% | 19.2% | 31.0% | 0.3 | 272.3B |
| 2022-2024 | 18.0% | 25.3% | -11.0% | 0.3 | 248.5B |
| 2023-2025 | -11.0% | 40.0% | -87.0% | 0.3 | 262.9B |

Overall, the company has shown varying levels of performance across different time periods, with a mix of positive and negative returns.

**Recent Stock Price Fluctuations**

* **Close Price:** $107.40
* **Last-Market:** $107.4, change: -0.72
* **5-Day SMA:** $109.06
* **20-Day SMA:** $108.56
* **60-Day SMA:** $100.24

The stock price is currently below its 5-day and 20-day moving averages, but above its 60-day moving average.

**RSI, PPO, and Delta_Previous_Relative_Divergence Analysis**

* **MRI (Market Risk Indicator):** 0.70
* **RSI (Relative Strength Index):** 49.89
* **PPO (Percentage Price Oscillator):** -0.58
* **Hybrid Signal:** Buy (Cash 0%)
* **Risk Level:** Medium (MRI 0.70)
* **Recent (20 days) relative divergence change:** -2.30 (-)
* **7-day Rank change:** 5 (+)
* **7-day Dynamic Expected Return change:** 23.20 (+)
* **Expected Return (%):** -6.40%

The RSI is at a level that suggests the stock is neither overbought nor oversold, while the PPO is bearish. The hybrid signal is buy, but with a cash allocation of 0%. The risk level is medium, and the expected return is negative.

**Recent News and Significant Events**

* [2026-01-26] Is Merck (MRK) Offering Value After Recent Share Price Pause And DCF Upside Signals - simplywall.st (link)
* [2026-01-26] Merck Chooses Evolution Over Revolution - At Proposed Price, I'm Not Surprised (NYSE:MRK) - Seeking Alpha (link)
* [2026-01-22] Merck Stock Capital Return Hits $91 Bil - Trefis (link)
* [2025-12-30] FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential - Yahoo Finance (link)
* [2026-01-26] Lbp Am Sa Buys 149,928 Shares of Merck & Co., Inc. $MRK - MarketBeat (link)
* [2026-01-26] Stock Movers: Revolution, USA Rare Earth, CoreWeave - Bloomberg.com (link)

There are several recent news and significant events related to the company, including a potential value opportunity, a choice between evolution and revolution, a record capital return, and the fast-tracking of two new drugs.

**Analyst Opinions**

* **Analyst Consensus:** Buy
* **Mean (1=StrongBuy~5=Sell):** 1.90 (~Buy)
* **Opinions:** 27
* **Target Price (avg/high/low):** 116.07 / 135.00 / 83.00

The analyst consensus is buy, with a mean rating of 1.90, indicating a moderate buy recommendation. The target price is set at an average of $116.07.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

The company's earnings per share (EPS) have ranged from $1.25 to $2.32 over the past few quarters, while revenue has been consistently high, peaking at $17.28 billion.

**Financial Information (Revenue and Profitability)**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

The company's revenue has been steadily increasing, while the profit margin has remained relatively high, ranging from 75.50% to 77.98% over the past few quarters.

**Financial Information (Capital and Profitability)**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

The company's equity has been increasing over the past few quarters, while the return on equity (ROE) has ranged from 7.09% to 11.16%.

**Comprehensive Analysis (Summary of previous items)**

The company has shown varying levels of performance across different time periods, with a mix of positive and negative returns. The stock price is currently below its 5-day and 20-day moving averages, but above its 60-day moving average. The RSI and PPO indicators suggest a bearish trend, while the hybrid signal is buy with a cash allocation of 0%. The risk level is medium, and the expected return is negative. The company has been consistently profitable, with a high revenue and profit margin. The equity has been increasing over the past few quarters, while the ROE has ranged from 7.09% to 11.16%. Overall, the company's performance has been mixed, with both positive and negative trends.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.